Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative GDC-0449 proof-of-mechanism study in resectable pancreatic ductal adenocarcinoma
ISRCTN13491559Phase 2Terminated
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Feb 2011
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vismodegib in pancreatic adenocarcinoma (PDAC), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Primary: effect on stromal cell and tumor cell Hedgehog signaling. Started Feb 2011; status: terminated.
02
Drugs
vismodegib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN13491559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13491559.